Debug Stats | ### Total Build Time: 24 ms 40.838 KB CONCEPT_NAME gt=3 ms Completed: 3 ms rowSize= 342 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 361 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 188 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=3 ms Completed: 3 ms rowSize= 548 bytesCONCEPT_CHILDREN gt=2 ms Completed: 2 ms rowSize= 557 bytesCONCEPT_ANCESTRAL_ROOTS gt=2 ms Completed: 2 ms rowSize= 4.058 KBCONCEPT_RELATIONSHIPS gt=6 ms Completed: 6 ms rowSize= 14.657 KBCONCEPT_GENES gt=8 ms Completed: 8 ms rowSize= 18.990 KBCONCEPT_XREFS gt=0 Completed: 0 ms rowSize= 1.156 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Relationships (46)
Relation Types: diso_to_anat : 17 diso_to_chem : 9 diso_to_diso : 16 diso_to_phen : 3 diso_to_phys : 1
Relationships: none : 22 is_abnormal_cell_of_disease : 5 is_associated_anatomic_site_of : 1 is_finding_of_disease : 1 is_normal_cell_origin_of_disease : 3 is_normal_tissue_origin_of_disease : 2 is_not_finding_of_disease : 1 is_primary_anatomic_site_of_disease : 1 isa : 6 may_be_finding_of_disease : 1 may_be_molecular_abnormality_of_disease : 2 permuted_term_of : 1 | |
DISO_to_DISO | 88 | |
Complication Aspects C1171258 | DISO_to_PHEN | 74 | |
genetic aspects C0017399 | DISO_to_ANAT | 51 | |
Mast Cells C0024880 | DISO_to_DISO | 44 | |
Complication Aspects C1171258 | DISO_to_PHEN | 39 | |
genetic aspects C0017399 | DISO_to_CHEM | 32 | |
Proto-Oncogene Protein c-kit C0072470 | DISO_to_CHEM | 20 | |
Pyrimidines C0034289 | DISO_to_ANAT | 18 | |
Mast Cells C0024880 | DISO_to_CHEM | 17 | |
Pyrimidines C0034289 | DISO_to_ANAT | 16 | |
In Blood C0005768 | DISO_to_CHEM | 16 | |
Proto-Oncogene Protein c-kit C0072470 | DISO_to_DISO | 16 | |
Anaphylaxis C0002792 | DISO_to_CHEM | 14 | |
Piperazines C0031958 | DISO_to_ANAT | 13 | |
Bone Marrow C0005953 | DISO_to_ANAT | 12 | |
Bone Marrow C0005953 | DISO_to_CHEM | 12 | |
Antineoplastic Agents C0003392 | DISO_to_CHEM | 12 | |
Piperazines C0031958 | DISO_to_CHEM | 9 | |
Antineoplastic Agents C0003392 | DISO_to_PHYS | 9 | |
Mutation C0026882 | DISO_to_CHEM | 8 | |
Protein Kinase Inhibitors C1449702 | DISO_to_DISO | 8 | |
Hypereosinophilic Syndrome C1540912 | DISO_to_DISO | 8 | |
Leukemia, Myelocytic, Acute C0023467 | DISO_to_ANAT | | is_associated_anatomic_site_of |
Bone Marrow C0005953 | DISO_to_ANAT | | is_normal_cell_origin_of_disease |
Bone Marrow Stem Cell C1511246 | DISO_to_ANAT | | is_abnormal_cell_of_disease |
Cancer Cell C0334227 |
|
Genes (16)
Species: human : 16 | |
Human | RASGRP4 | 115727 | RAS guanyl releasing protein 4 | INFERRED, Score=800, UMLKSK CUI: C0221013 | Human | FIP1L1 | 81608 | factor interacting with PAPOLA and CPSF1 | FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis | Human | CHIC2 | 26511 | cysteine-rich hydrophobic domain 2 | CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. used fluorescence in situ hybridization to detect deletion of the CHIC2 locus at 4q12 as a surrogate for the FIP1L1-PDGFRA fusion and was observed in bone marrow cells for 3 of 5 patients with systemic mast cell disease associated with eosinophilia | Human | MRAS | 22808 | muscle RAS oncogene homolog | INFERRED, Score=800, UMLKSK CUI: C0221013 | Human | SLC18A2 | 6571 | solute carrier family 18 (vesicular monoamine transporter), member 2 | Vesicular Monoamine Transporter 2 (VMAT2) Expression in Hematopoietic Cells and in Patients with Systemic Mastocytosis. | Human | SERPINB9 | 5272 | serpin peptidase inhibitor, clade B (ovalbumin), member 9 | In addition, in 80% of all cases of cutaneous and systemic mastocytosis tested the majority of the mast cells expressed PI9. | Human | ENPP3 | 5169 | ectonucleotide pyrophosphatase/phosphodiesterase 3 | Several of these antigens (CD2, CD25, CD35, CD88, CD203c) appear to be upregulated on MCs in patients with systemic mastocytosis and therefore are used as diagnostic markers. | Human | PDGFRA | 5156 | platelet-derived growth factor receptor, alpha polypeptide | Although bone marrow biopsies in these patients showed increased numbers of CD25+ mast cells and atypical spindle-shaped mast cells, patients with HES and elevated serum tryptase could be distinguished from patients with systemic mastocytosis and eosinophilia by their clinical manifestations, the absence of mast cell aggregates, the lack of a somatic KIT mutation, and the presence of the recently described fusion of the Fip1-like 1 (FIP1L1) gene to the platelet-derived growth factor receptor alpha gene (PDGFRA). | Human | NTRK3 | 4916 | neurotrophic tyrosine kinase, receptor, type 3 | INFERRED, Score=800, UMLKSK CUI: C0221013 | Human | KIT | 3815 | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). These data suggest that KIT(D816V+) systemic mastocytosis (SM) can co-exist with JAK2(V617F+) chronic idiopathic myelofibrosis (CIMF) and in some of these SM-CIMF cases, the two mutations are present in the neoplastic cells of both disease components Dysregulated kit function is an important component of oncogenesis in a large number of neoplastic disorders, including systemic mastocytosis rapamycin induction of apoptosis appears specific to the C-Kit D816V mutation in systemic mastocytosis Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene | Human | ITGB1 | 3688 | integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | INFERRED, Score=800, UMLKSK CUI: C0221013 | Human | ITGAV | 3685 | integrin, alpha V | INFERRED, Score=800, UMLKSK CUI: C0221013 | Human | IL2RA | 3559 | interleukin 2 receptor, alpha | Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis and can be used to confirm the diagnosis | Human | CSF1 | 1435 | colony stimulating factor 1 (macrophage) | We report the in vitro and in vivo effects of granulocyte macrophage colony stimulating factor (GM-CSF), a known inhibitor of in vitro mast cell differentiation, in a patient with benign, adult-onset systemic mastocytosis. | Human | BTK | 695 | Bruton agammaglobulinemia tyrosine kinase | INFERRED, Score=800, UMLKSK CUI: C0221013 | Human | BCL2L1 | 598 | BCL2-like 1 | In contrast to the skin lesions, bone marrow infiltrates of patients with systemic mastocytosis showed only low or absent immunoreactivity for bcl-2, but marked expression of bcl-xL. |
|